


**BOOK EARLY  
AND SAVE €200**

**June 26-28 2018 | Frankfurt**

[www.oncolytic-immunotherapies.com](http://www.oncolytic-immunotherapies.com)



# Armed Oncolytic Immunotherapies Summit

**Accelerate the Development  
of Targeted Oncolytic  
Immunotherapies in Combination  
as the Cornerstone Therapeutic  
Modality for Oncology**

## Expert Speakers Include:



**Akseli Hemminki**  
Founder, Chief Executive  
Officer & Chairman of the  
Board  
**TILT Biotherapeutics**



**Daniel Katzman**  
Chief Executive  
Officer  
**Unleash Immuno  
Oncolytics**



**Colin Love**  
Chief Operating Officer  
**Replimune**



**Gabriella Campadelli-  
Fiume**  
Professor, **University of  
Bologna** & Co-founder of  
**NousCom**



**Frank Tufaro**  
Chief Executive Officer  
**DNatrix**



**Stephen Russell**  
Chief Executive Officer  
**Vyriad**

**Partner**



**Tel:** +44 (0)20 3141 8700

**Email:** [info@hansonwade.com](mailto:info@hansonwade.com)

 **Oncolytic Viruses**



# Welcome to the Armed Oncolytic Immunotherapies Summit

**The leading industry focused meeting that explores optimal arming payloads and rational combinations to advance the clinical development of oncolytic immunotherapies.**

After the first OV approval three years ago we have seen enhanced efficacy and recent success in using oncolytic viruses and microbes in combination. This meeting delves into the next generation of oncolytic immunotherapies with the greatest potential for clinical and commercial success – **armed oncolytic immunotherapies in combination.**

Join the expert leaders of the immuno-oncolytic community to discuss the most up-to-date clinical advances alongside novel therapeutic strategies to increase potency, targeting and immune cell recruitment in the effort to turn cold tumours hot.

**The Armed Oncolytic Immunotherapy Summit** is your opportunity to develop your oncolytic pipeline through lessons learned in the clinic and optimizing combination therapies.

Future-proof your manufacturing strategies and ensure scale up of quality viruses for large scale clinical trials.

This meeting offers the platform for immuno-oncology developers to network and create collaborative partnerships with the leaders developing the next generation of oncolytic immunotherapies.

Leave this meeting well equipped to develop an efficacious, safe and potent oncolytic virus or microbe in combination.

**What previous Oncolytic Virotherapy Summit attendees have said about our meetings**

“ This summit provided great talks. Topics were focused and inspiring. The oncolytic virotherapy community was enthusiastic and full of ideas ”

MIT

“ Extremely useful conference to meet other players in the modern OV development, which will make a change in how we are going to treat diseases like cancer ”

Boehringer  
Ingelheim

## Your Checklist to Accelerate the Clinical Development of Your Oncolytic Immunotherapy

1.

**Rational Combination Therapies to Advance Existing Standards of Care**


Listen to **Amgen** and **Tilt Biotherapeutics** as they reveal clinical outcomes of armed oncolytic viruses in combination with tumour-infiltrating lymphocytes, immune checkpoint inhibitors, monoclonal antibodies and CAR-T adoptive therapies



2.

**Arming Strategies to Enhance Clinical Efficacy**

Learn from the strategies of **Unleash Immuno Oncolytics** and **NousCom** as they divulge the scientific concepts behind their arming payloads to increase the potency of anticancer vaccines



3.

**Manufacturing Consideration to Produce Quality Armed Viruses to Accelerate Clinical Advancement**


Identify ways to refine your manufacturing strategy to improve the quality and quantity of your virus when scaling up for large scale clinical trials with talks from **Turnstone Biologics**



4.

**Identify Predictive Preclinical Models to Ensure Reliable Human Translation**

Join the discussion with **ViraTherapeutics** and **Unleash Immuno Oncolytics** to explore the most appropriate model to ensure reliable data is collected to make translatable preclinical conclusions



5.

**Current Status for Systemic Delivery of Viral Therapy**

Learn from **Vyriad** to improve your strategies to enhance the systemic delivery of oncolytic viruses to create an un-invasive delivery system which has increased viral spread



## Your Expert Speakers



**Jing Qing**  
Global Discovery  
Research Lead for  
IMLYGIC  
**Amgen**



**Jung-Joon Min**  
Professor & Chair,  
Department of  
Nuclear Medicine  
**Chonnam National  
University Medical  
School**



**Frank Tufaro**  
Chief Executive  
Officer  
**DNatrix**



**Hyam Levitsky**  
Executive Vice  
President of  
Research & Chief  
Scientific Officer  
**Juno Therapeutics**



**Noriyuki Kasahara**  
Professor,  
Department  
of Cell Biology &  
Pathology  
**University of  
Miami**



**Frederick Lang**  
Professor & Chair of  
Clinical Research,  
Department of  
Neurosurgery  
**MD Anderson**



**Gabriella  
Campadelli-Fiume**  
Professor, **University  
of Bologna** & Co-  
founder of **NousCom**



**Jean-Simon Diallo**  
Assistant Professor,  
Biochemistry,  
Microbiology &  
Immunology  
**University of  
Ottawa**



**John Bell**  
Professor of  
Medicine  
**Ottawa Health  
Research  
Institute**



**Colin Love**  
Chief Operating  
Officer  
**Replimune**



**Akseli Hemminki**  
Founder, Chief  
Executive Officer  
& Chairman of the  
Board  
**TILT  
Biotherapeutics**



**Julia Pomoransky**  
Manager,  
Manufacturing  
Sciences &  
Technology  
**Turnstone Biologics**



**Eric Quemeneur**  
Executive Vice  
President  
**Transgene S.A**



**Daniel Katzman**  
Chief Executive  
Officer  
**Unleash Immuno  
Oncolytics**



**David Curiel**  
Director, Biologic  
Therapeutics Center  
Washington  
**University School  
of Medicine**



**Michael Stein**  
Executive Chairman  
**Valo Therapeutics**



**Patrik Erlmann**  
Head of Research &  
Development  
**ViraTherapeutics**



**Stephen Russell**  
Chief Executive  
Officer  
**Vyriad**



**Hideki Kasuya**  
Director & Professor,  
Cancer Immune  
Therapy Center  
**Nagoya University**

One of the most efficient and valuable opportunities  
to overview the field and meet the key developers  
Past CVI Summit Attendee, AGC Business, Development Americas

## Conference Day One | Wednesday 27th June 2018

|                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  <p><b>Frank Tufaro</b><br/>Chief Executive<br/>Officer<br/><b>DNatrix</b></p> | <p><b>9.00 Chair's Opening Remarks</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <p><b>Manufacturing Strategies to Produce Quality Armed Viruses to Future-Proof Plans of Large Scale Trials</b></p>                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <p><b>Julia Pomoransky</b><br/>Manager,<br/>Manufacturing<br/>Sciences &amp;<br/>Technology<br/><b>Turnstone Biologics</b></p>                                 | <p><b>9.10 Developing a CMC Strategy for Oncolytic Virus based Cancer Immunotherapy</b></p> <ul style="list-style-type: none"> <li>• Oncolytic vaccine development is anchored in the analytical toolbox developed</li> <li>• Applying Quality-by-Design principles, including defining a Target Product Profile to help frame scope for development</li> <li>• Accurate assessments of potency in the context of dose (safety and efficacy), stability, and manufacturing productivity are critical</li> <li>• Integrating the above leads to a CMC development plan that is phase appropriate, and can stay ahead of your clinical development plan</li> </ul>                                                                                                                                                        |
| <p><b>Colin Love</b><br/>Chief Operating<br/>Officer<br/><b>Replimune</b></p>                                                                                  | <p><b>9.40 Overcoming the Manufacturing Challenges in Taking Novel Oncolytic Immunotherapy</b></p> <ul style="list-style-type: none"> <li>• Replimune has developed a new oncolytic immunotherapy platform which aims to maximize the robust virus-mediated destruction of tumors combined with the stimulation of potent anti-tumor immune responses to provide systemic clinical benefit</li> <li>• With a pipeline of new oncolytic immunotherapy products the pathway from design to initial clinical trials should be rapid and robust</li> <li>• Manufacturing strategy is key to ensuring a smooth transition from early phase clinical trials in to pivotal clinical trials</li> <li>• Armed oncolytic immunotherapies will provide some unique manufacturing challenges during the approval process</li> </ul> |

### 10.10 Panel Discussion: Strategies to Accelerate Movement into Early Stage Clinical Development with Future Focused Plans for Mature Commercialisation

- Identify the full product development of early stage clinical concepts
- Strategies to reduce the time taken to move into clinical trials
- Plan for success by considering regulatory strategies for mature commercialisation of viral therapies
- Explore different manufacturing standards in Europe



**Julia Pomoransky**  
Manager, Manufacturing  
Sciences & Technology  
**Turnstone Biologics**



**Colin Love**  
Chief Operating Officer  
**Replimune**



**Eric Quemeneur**  
Executive Vice President  
**Transgene S.A**

|  |                                                               |
|--|---------------------------------------------------------------|
|  | <p><b>10.40 Morning Refreshments and Speed Networking</b></p> |
|--|---------------------------------------------------------------|

## Strategies to Arm the Virus to Enhance Clinical Efficacy

**Gabriella Campadelli-Fiume**  
Professor, **University of Bologna** & Co-founder of **NousCom**

### 11.40 Durable Immunotherapeutic Effects and Abscopal Efficacy of a HER2-Retargeted IL12-Armed oHSV

- HER2-retargeted oHSV are fully virulent for their HER2-pos target cells. They carry no deletion/mutation or genetic change other than those necessary for tropism modification. They are highly safe in mice
- Unlike most o-HSVs, which fail to contrast innate response, fully-virulent oHSV elicit and then dampen innate response. The immunotherapeutic potential of the HER2-retargeted fully virulent oHSVs was unknown
- A IL12-armed HER2-retargeted oHSV elicits a strong immunotherapeutic effect, fully protects from distant tumors, unleashes the immunosuppression by recruiting and activating NK and CD8+ cells. A durable immunity is established
- The HER2-retargeted oHSVs act as potent anticancer vaccines

**Akseli Hemminki**  
Founder, Chief Executive Officer & Chairman of the Board  
**TILT Biotherapeutics**

### 12.10 Enabling T-Cell Therapies for Solid Tumors with Armed Oncolytic Adenoviruses

- Observations and data from Advanced Therapy Access Program and research conducted by Univ. of Helsinki CGTG leading to founding of TILT
- About the lead product TILT-123, a TNFα/IL2 armed oncolytic adenovirus, for which 100% efficacy has been demonstrated with TILs, αPD1, and CAR-T
- Overview of TILT Biotherapeutics' Phase I trial plans with TILT-123

**Noriyuki Kasahara**  
Professor,  
Department of Cell Biology & Pathology  
**University of Miami**

### 12.40 Retroviral Replicating Vectors for Armed Oncolytic Immunovirotherapy

- Retroviral replicating vectors can efficiently deliver a wide variety of transgenes, including pro-drug activator ('suicide') genes, which convert systemically administered precursor pro-drugs into active cytotoxic drugs within the infected cancer cells
- Clinical trials of Toca 511, an optimized RRV expressing the yeast cytosine deaminase prodrug activator gene, have shown highly promising evidence of therapeutic benefit. An international Phase III trial for recurrent high-grade glioma is currently on-going, as well as a new Phase I trial for intravenous delivery of Toca 511 in systemic malignancies
- New directions for further translational application of efficient and stable tumor transduction enabled by RRV-mediated gene transfer include delivery of pro-mutagenic drug activator genes, shRNA targeting immune checkpoints, immunostimulatory cytokines, and immunodominant neo-antigenic epitopes

### 13.10 Lunch and Networking

**Eric Quemeneur**  
Executive Vice President  
**Transgene S.A**

### 14.10 InvirIO® : Immuno-Armed Oncolytic Vaccinia Viruses to Reprogram the Tumor Microenvironment

- Oncolytic vaccinia virus (oVV) represents an appealing engineering platform, by exploiting its favorable immunogenic properties, and its large genome capacity
- Our experience with two products in clinics (PexaVec, and TG6002), and one preclinical product (VV-αPD1) already exemplified the feasibility of amplifying the oncolytic action by additional delivery of either a cytokine, an enzyme, or an antibody into the tumor microenvironment
- We are currently developing recombinant oVVs that express various modalities to break immune tolerance in the tumor, for example by modulating the content of immunosuppressive cells or metabolites

**Daniel Katzman**  
Chief Executive Officer  
**Unleash Immuno Oncolytics**

### 14.40 Immunizing CRAd for Carcinoma of the Ovary

- Current models do not allow full assessment of anti-tumor immunization of adenovirus virotherapy agents
- We have identified a replication-permissive immunocompetent murine model of cancer of the ovary
- The model helps identify the most potent immunotherapy arming for our tumor targeted CRAds to determine the most effective anti-tumor immunization

|                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                    | <b>15.10 Afternoon Refreshments</b>                                                                                                                                                                                                                                                                                                                                          |
|  <b>Michael Stein</b><br>Executive Chairman<br><b>Valo Therapeutics</b>                                                            | <b>15.40 Valo Therapeutics: Reinventing Cancer Immunotherapy</b> <ul style="list-style-type: none"> <li>• PeptiCRAd technology: A therapeutic vaccination against cancer</li> <li>• Mechanisms of Action: Educating the immune system to recognise and target tumour cells</li> <li>• Preliminary Data: PeptiCRAd generates a strong anti-tumor immune response</li> </ul>   |
| <b>Clinical Developments of Oncolytic Bacteria</b>                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                              |
|  <b>Jung-Joon Min</b><br>Professor & Chair,<br>Department of Nuclear Medicine<br><b>Chonnam National University Medical School</b> | <b>16.10 Engineered Salmonella typhimurium for Enhancement of Anti-Cancer Immunity</b> <ul style="list-style-type: none"> <li>• Payloads expressed and delivered by attenuated Salmonella for anti-cancer immunity</li> <li>• Mechanism of Salmonella-mediated cancer therapy</li> <li>• Strategies for imaging and monitoring Salmonella-mediated cancer therapy</li> </ul> |
|  <b>Frank Tufaro</b><br>Chief Executive Officer<br><b>DNatrix</b>                                                                 | <b>16.40 Chair's Closing Remarks</b>                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                    | <b>16.45 End of Day 1</b>                                                                                                                                                                                                                                                                                                                                                    |

Very well organized, relaxed setting conducive to interactions among attendees and speakers

**MedImmune - Previous Oncolytic Virotherapy Attendee**



## Conference Day Two | Thursday 28th June 2018

|                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  <b>Frank Tufaro</b><br>Chief Executive Officer<br><b>DNAtrix</b> | <b>9.00 Chair's Opening Remarks</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Avenues to Rational Combination Therapies to Advance Existing Standards of Care</b>                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Jing Qing</b><br>Global Discovery Research Lead for IMLYGIC<br><b>Amgen</b>                                                                    | <b>9.10 Mechanisms of IMLYGIC, the Bedside to Bench Learning Loop</b> <ul style="list-style-type: none"> <li>• Introduction to IMLYGIC and the summary of OPTiM Ph.III trial</li> <li>• MOA studies of IMLYGIC using preclinical models, as a single agent and in combination with checkpoint blockade</li> <li>• Early insights into clinical activities of IMLYGIC in combination with Ipilimumab and Pembrolizumab</li> </ul>                                                                                                                                                                                                                                                                                                                              |
| <b>Jean-Simon Diallo</b><br>Assistant Professor, Biochemistry, Microbiology & Immunology<br><b>University of Ottawa</b>                           | <b>9.40 Small Molecule Enhancers of Oncolytic Immunotherapy</b> <ul style="list-style-type: none"> <li>• Novel small molecules termed "viral sensitizers" work in a variety of ways to deter the immune response away from the virus, allowing for vastly improved infection</li> <li>• Here we will present recent data highlighting the capacity of vanadium-based compounds to shift type I antiviral responses towards a type II pro-inflammatory phenotype that favours adaptive anti-tumor effects</li> <li>• We will also present our recent findings regarding the effectiveness of targeting NF-κB nuclear translocation using both novel and approved drugs as in combination with oncolytic viruses <i>in vitro</i> and <i>in vivo</i>.</li> </ul> |
|                                                                                                                                                   | <b>10.10 Morning Refreshments</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Hideki Kasuya</b><br>Director & Professor, Cancer Immune Therapy Center<br><b>Nagoya University</b>                                            | <b>11.10 Overview of the Immunotherapy Combinations with HF10 from Clinical Trial and Basic Research</b> <ul style="list-style-type: none"> <li>• Overview of clinical trial using HF10 in Japan and USA</li> <li>• New generation of HF10 with immune related therapeutic molecules</li> <li>• New strategy of oncolytic virus with CAR T-cell</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                    |

### 11.40 Panel Discussion: Explore Novel Approaches to Identify the Most Rational Combinations

- What virus is best evolved to add a measurable contribution in a combination therapy
- Methods to identify and quantify if the virus is importantly contributing to the outcome of therapy



**Akseli Hemminki** Founder, Chief Executive Officer & Chairman of the Board  
**TILT Biotherapeutics**



**John Bell** Professor of Medicine  
**Ottawa Health Research Institute**



**Jing Qing** Global Discovery Research Lead for IMLYGIC  
**Amgen**



**Stephen Russell** Chief Executive Officer  
**Vyriad**



**Hyam Levitsky** Executive Vice President of Research & Chief Scientific Officer  
**Juno Therapeutics**

|                                                                                    |                                                                                                                                                                                                                                                                                                                              |
|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                    | <b>12.40 Lunch and Networking</b>                                                                                                                                                                                                                                                                                            |
| <b>Current Status for Systemic Delivery of Viral Therapy</b>                       |                                                                                                                                                                                                                                                                                                                              |
| <b>Patrik Erlmann</b><br>Head of Research & Development<br><b>ViraTherapeutics</b> | <b>13.40 VSV-GP Therapy is Effective Though Direct Tumor Lysis and Stimulation of an Anti-Tumor Immune Response</b> <ul style="list-style-type: none"> <li>• I.T. vs. I.V. in mouse tumor models</li> <li>• VSV-GP as potent OV for I.V. therapy</li> <li>• Benefits and handicaps of I.V. treatment of armed OVs</li> </ul> |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p><b>Stephen Russell</b><br/>Chief Executive Officer<br/><b>Vyriad</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                              | <p><b>14.10 Systemic Cancer Therapy Using Oncolytic VSVs: The Voyager Platform</b></p> <ul style="list-style-type: none"> <li>VSV is a low seroprevalence RNA virus with extensively studied oncolytic activity</li> <li>Vyriad is developing this platform for systemic single cycle virotherapy, both as stand-alone therapy and in combination with other IO agents</li> <li>Clinical and preclinical progress will be discussed</li> </ul>                                               |
| <p><b>Frederick Lang</b><br/>Professor &amp; Chair of Clinical Research, Department of Neurosurgery<br/><b>MD Anderson</b></p>                                                                                                                                                                                                                                                                                                                                                                                                           | <p><b>14.40 Biological Therapies for Gliomas - Oncolytic Viruses and Bone Marrow Derived Mesenchymal Stem Cells</b></p> <ul style="list-style-type: none"> <li>The delivery of oncolytic virotherapy has been a challenge with current methods depending on intratumoral delivery</li> <li>Stem cells have been a potential solution to overcome this challenge</li> <li>This talk will outline the use of bone marrow derived mesenchymal stem cells for the delivery of DNX2401</li> </ul> |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | <p><b>15.10 Afternoon Refreshments</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <p><b>Efficacious Preclinical Models which show Best Human Translation</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <p><b>16.10 Panel Discussion : Animal Model Systems to Predict Human Translation</b></p> <ul style="list-style-type: none"> <li>Discuss the most appropriate model to ensure reliable data is collected to make preclinical conclusions</li> <li>Explore past clinical data to acknowledge the quality of the preclinical models</li> <li>Explore varying infections in different specie cell types and difficulty in assessing presentation</li> <li>Determine and develop transgenic models to increase translation results</li> </ul> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <p> <b>Patrik Erlmann</b><br/>Head of Research &amp; Development<br/><b>ViraTherapeutics</b></p>                                                                                                                                                                                                                                                                                                                                                      | <p> <b>Daniel Katzman</b><br/>Chief Executive Officer<br/><b>Unleash Immuno Oncolytics</b></p>                                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | <p> <b>Noriyuki Kasahara</b><br/>Professor, Department of Cell Biology &amp; Pathology<br/><b>University of Miami</b></p>                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | <p> <b>David Curiel</b><br/>Director, Biologic Therapeutics Center<br/>Washington<br/><b>University School of Medicine</b></p>                                                                                                                                                                                                                                                                          |
| <p><b>Frank Tufaro</b><br/>Chief Executive Officer<br/><b>DNAtrix</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                | <p><b>16.40 Biomarkers to Track and Measure Clinical Efficacy</b></p> <ul style="list-style-type: none"> <li>Explore what biomarkers should be used to test efficacy in preclinical studies</li> <li>Experience from GBM clinical trials</li> </ul>                                                                                                                                                                                                                                          |
| <p> <b>Frank Tufaro</b><br/>Chief Executive Officer<br/><b>DNAtrix</b></p>                                                                                                                                                                                                                                                                                                                                                                             | <p><b>17.10 Chair's Closing Remarks</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | <p><b>17.15 End of Day 2</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

Extraordinary and valuable niche meeting to follow the exciting growth of oncolytic virotherapies

**Unleash Immuno Oncolytics**

## Pre-Conference Workshop Day | Tuesday 26th June 2018

### Workshop A

## Identify the Next Generation of Armed Therapeutics in Combination

9:00am - 12:00pm

As the hottest area of oncolytic immunotherapies is the arming of viruses in line with combinational therapy approaches, this workshop will provide the opportunity to engage in an in-depth discussion exploring the future of armed therapeutics.

Join this workshop to identify the ideal arming payloads and combination strategies to improve your immuno-oncolytic pipeline.

#### Attend this session to discuss:

- What characteristics should be engineered or selected for, to create the optimal oncolytic virus?
- What are the best “*cis and/or trans*” combination approaches to enhance both viral oncolysis and anti-tumor immune responses?
- Classes of transgenes that could be encoded into an OV backbone?
- What are the challenges and advantages to encoding multiple payloads within a single oncolytic virus therapeutic?



#### Workshop Leader

**John Bell**, Professor of Medicine, **Ottawa Health Research Institute**

John Bell is an international leader in the development of oncolytic viruses that selectively infect and kill cancer cells, while leaving healthy tissues unharmed. His research lab focuses on the discovery/design of oncolytic viruses, their manufacture and clinical translation. He is a Scientific Co-founder of Turnstone Biologics which is clinically testing

rabdovirus based oncolytic virus vaccine products and a novel vaccinia virus platform encoding multiple therapeutic transgenes. John is a Senior Scientist at the Ottawa Hospital Research Institute and the Scientific Director of a Canadian National Network (BioCanRx) aimed at translating Anti-Cancer Biotherapeutics from the laboratory into the Clinic.

### Workshop B

## Novel Forms of Delivery for Oncolytic Immunotherapies

13:00pm - 16:00pm

One of the greatest challenges in this therapeutic area is the use of an un-invasive delivery system that is able to travel intravenously to the tumor site and overcome the immune system response. This workshop explores the hurdles using intravenous delivery compared to a systemic approach of intravenous delivery.

#### Attend this session to discuss:

- Novel forms of delivery devices for intravenous delivery
- Explore the hurdles limiting systemic delivery
- Identify the benefits and handicaps of intratumoral delivery



#### Workshop Leader

**David Curiel**, Director, Biologic Therapeutics Center, **Washington University School of Medicine**

David is a top scientific leader with broad experience in oncolytic virus: research and development as well as founding and managing biotech start-ups.

He is the Director of the Cancer Biology Division and Director of the Biologics Therapeutics – Washington University School of Medicine.

David has published numerous peer reviewed papers in prestigious scientific publication magazines.

Previously Dr. Curiel was the Chief Scientific Officer & founder of VectorLogics, a company developing oncolytic virus therapies. Vectorlogics merged with DNATrix in 2012.

# PARTNER



## Partner

Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. [www.transgene.fr](http://www.transgene.fr)

## COMPANIES PREVIOUSLY ATTENDED



### TYPICAL ATTENDANCE SENIORITY



C-level Executives: 37%

Director Level  
and Above: 16%

Head of: 20%

Scientist: 27%

### ESTIMATED ATTENDANCE BY INDUSTRY TYPE

70% Drug Developers

17% Academics

11% Solution & Service Providers

2% Investors & Analysts

\*Based on market research and previous events' statistics

**BECOME A  
COMMERCIAL PARTNER**



**Jonathan Kilby-Phillips**  
Commercial Manager  
Tel: +44 (0)20 3141 8700  
Email: [sponsor@hansonwade.com](mailto:sponsor@hansonwade.com)

# READY TO REGISTER?

## 3 EASY WAYS TO BOOK



[www.oncolytic-immunotherapies.com/register](http://www.oncolytic-immunotherapies.com/register)



Tel: +44 (0)20 3141 8700



Email: [register@hansonwade.com](mailto:register@hansonwade.com)

- 1 Learn** from the leading experts in the immuno-oncology community and join the discussion to overcome key challenges limiting this space
- 2 Hear** the most successful clinical case studies and novel therapeutic strategies to increase the efficacy of your armed oncolytic immunotherapy
- 3 Network** with pioneering leaders and experts of the immuno-oncology community and take this opportunity to create collaborative partnerships for future clinical prospects

### Team Discounts\*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.


## SECURE YOUR PLACE

| Oncolytic Immunotherapy Developer Pricing* | Register & Pay before<br>25/05/2018 (Save up to €200!) | Standard Pricing |
|--------------------------------------------|--------------------------------------------------------|------------------|
| Conference Only                            | €1,599.00                                              | € 1,799.00       |
| Conference + 1 Workshop                    | €1,998.00                                              | €2,198.00        |
| Conference + 2 Workshops                   | €2,397.00                                              | €2,597.00        |
| Workshops (Each)                           | €499.00                                                |                  |

\*Must currently and publicly be developing an in pipeline oncolytic virus/microbe therapy

| Academic Pricing         | Register & Pay before<br>25/05/2018 (Save up to €200!) | Standard Pricing |
|--------------------------|--------------------------------------------------------|------------------|
| Conference Only          | €1,199.00                                              | €1,399.00        |
| Conference + 1 Workshop  | €1,598.00                                              | €1,798.00        |
| Conference + 2 Workshops | €1,997.00                                              | €2,197.00        |
| Workshops (Each)         | €499.00                                                |                  |

| Solution/ Service Provider Pricing | Register & Pay before<br>25/05/2018 (Save up to €200!) | Standard Pricing |
|------------------------------------|--------------------------------------------------------|------------------|
| Conference Only                    | €2,199.00                                              | €2,399.00        |
| Conference + 1 Workshop            | €2,698.00                                              | €2,898.00        |
| Conference + 2 Workshops           | €3,097.00                                              | €3,297.00        |
| Workshops (Each)                   | €599.00                                                |                  |



## VENUE

**Le Méridien Frankfurt**  
Wiesenhuettenplatz 28-38, Frankfurt,  
60329, Germany  
For further information or assistance, please  
visit [www.lemeridienfrankfurt.com](http://www.lemeridienfrankfurt.com)

### TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 9770